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Abstract
Background: The metabolism of xenobiotics plays an essential role in smoking related lung
function loss and development of Chronic Obstructive Pulmonary Disease. Nuclear Factor
Erythroid 2-Like 2 (NFE2L2 or NRF2) and its cytosolic repressor Kelch-like ECH-associated
protein-1 (KEAP1) regulate transcription of enzymes involved in cellular detoxification processes
and Nfe2l2-deficient mice develop tobacco-induced emphysema. We assessed the impact of Single
Nucleotide Polymorphisms (SNPs) in both genes on the level and longitudinal course of Forced
Expiratory Volume in 1 second (FEV1) in the general population.
Methods: Five NFE2L2 and three KEAP1 tagging SNPs were genotyped in the population-based
Doetinchem cohort (n = 1,152) and the independent Vlagtwedde-Vlaardingen cohort (n = 1,390).
On average 3 FEV1 measurements during 3 surveys, respectively 7 FEV1 measurements during 8
surveys were present. Linear Mixed Effect models were used to test cross-sectional and
longitudinal genetic effects on repeated FEV1 measurements.
Results: In the Vlagtwedde-Vlaardingen cohort SNP rs11085735 in KEAP1 was associated with a
higher FEV1 level (p = 0.02 for an additive effect), and SNP rs2364723 in NFE2L2 was associated
with a lower FEV1 level (p = 0.06). The associations were even more significant in the pooled cohort
analysis. No significant association of KEAP1 or NFE2L2 SNPs with FEV1 decline was observed.
Conclusion:  This is the first genetic study on variations in key antioxidant transcriptional
regulators KEAP1 and NFE2L2 and lung function in a general population. It identified 2 SNPs in
NFE2L2 and KEAP1 which affect the level of FEV1 in the general population. It additionally shows
that NFE2L2 and KEAP1 variations are unlikely to play a role in the longitudinal course of FEV1 in
the general population.
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Background
The mortality and morbidity of Chronic Obstructive Pul-
monary Disease (COPD) has been increasing over the
past decades and the disease is a fundamental medical
and economical problem in Western societies [1]. A
genetic predisposition is thought to play a crucial role in
the onset of COPD and the heritability of lung function
loss that precedes COPD development has been clearly
established [2,3]. Several polymorphisms have been iden-
tified in association with level of lung function, but sub-
sequent studies have failed to replicate these reported
associations [4,5]. So far, only a small subset of polymor-
phisms has been consistently replicated in their associa-
tion with COPD development or lung function decline
across independent studies or populations [6-11].
Nuclear Factor (Erythroid-derived 2)-Like 2 (NFE2L2 or
NRF2) regulates the transcription of numerous antioxi-
dant enzymes in response to oxidant injury, via direct
binding to the antioxidant responsive element in the tar-
get gene [12-15]. It therefore is a potent candidate gene for
excess lung function loss and COPD development.
Kelch-like ECH-associated protein-1 (KEAP1) is a
cytosolic repressor of NFE2L2. Oxidative stress causes dis-
ruption of the KEAP1-NFE2L2 complex, translocation of
NFE2L2 to the nucleus and subsequent induction of the
expression of antioxidant genes [16]. It has been shown
that Nfe2l2  protects mice against elastase-induced [17]
and tobacco-induced [18] emphysema. Additionally, the
expression pattern of both KEAP1 and NFE2L2 is different
in COPD patients as compared to healthy never- or
former- smokers [19,20] and the expression of NFE2L2-
regulated antioxidant genes is lower in COPD subjects
than in non-diseased controls [21]. Three new polymor-
phisms have been discovered in the promoter region of
NFE2L2, but these were not associated with COPD in a
Japanese population [22]. One study showed that one of
these polymorphisms decreases NFE2L2  expression  in
vitro and is associated with development of acute lung
injury in a Caucasian population [23]. So far no studies
have investigated the role of NFE2L2 or KEAP1 polymor-
phisms in relation to the longitudinal course of lung func-
tion in the general population.
Therefore, in the current study we investigated whether
NFE2L2 or  KEAP1  polymorphisms affect the level and
longitudinal course of FEV1 (Forced Expiratory Volume in
1 second), both being important risks for COPD [24]. In
order to assure consistency of results, we performed this




Subjects from the Doetinchem cohort study [25], a pro-
spective part of the MORGEN study [26], were included.
A sub-sample (n = 1,152 subjects with 3,115 FEV1 meas-
urements during 3 surveys: surveys 1993–1997 (n =
1,152), 1998–2002 (n = 1,152), and 2003–2007 (n =
811)), table 1) was randomly selected from the total
cohort with spirometry tests and DNA available as
described previously [27]. FEV1 was measured three times
(maneuver performed with a heated pneumotachograph
(Jaeger, Germany)) with 5-year intervals according to the
European Respiratory Society (ERS) guidelines [28].
An independent cohort (Vlagtwedde-Vlaardingen; n =
1,390 subjects with 8,159 FEV1 measurements during 8
surveys, table 1) was additionally studied. This cohort was
prospectively followed for 25 years with FEV1 measure-
ments (maneuver performed with a water-sealed spirom-
eter (Lode Instruments, the Netherlands)) every 3 years
(following ERS guidelines) [29].
The study protocols were approved by local medical ethics
committees and all participants gave their written
informed consent.
Selection/genotyping of Single Nucleotide Polymorphisms 
(SNPs)
We pairwise tagged NFE2L2 and KEAP1 with respectively
five and three SNPs according to the HapMap CEU geno-
type data (23a) with an r2 threshold of 0.8 and Minor
Allele Frequency (MAF)>5%. We additionally included
three novel NFE2L2 polymorphisms [22] with MAF>5%:
G(-686)A (rs35652124), C(-650)A (rs6721961) and Tri-
nucleotide CCG Repeat (TNR). SNPs were genotyped by
K-Bioscience Ltd (UK) using their patent-protected com-
petitive allele specific PCR system (KASPar). The addi-
tional file 1 contains details on SNP-selection and
NFE2L2 TNR genotyping.
Statistics
SNPs in NFE2L2 and KEAP1 and level of FEV1
We used Linear Mixed Effect (LME) to study the effects of
SNPs and haplotypes (additive genetic model; coded: 0 =
homozygote wild type, 1 = heterozygote, 2 = homozygote
mutant) on the level of FEV1 in both cohorts separately,
using all available FEV1 measurements across all surveys.
This analysis was adjusted for age (defined with natural
cubic spline with 4 degrees of freedom in order to take
into account varying effects of age on the level of FEV1
throughout lifetime), sex, packyears smoked, height and
the correlation of FEV1 measurements within each subject
(random effect assigned to the intercept).Respiratory Research 2009, 10:73 http://respiratory-research.com/content/10/1/73
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SNPs in NFE2L2 and KEAP1 and course of FEV1
We studied the effect of SNPs on course of FEV1 by intro-
ducing the interaction term of SNP × time (defined in rela-
tion to the first FEV1 measurement and with random effect
assigned) into the primary analysis model described
above (see additional file 1 for details).
Analysis on the pooled cohorts
Finally, we pooled both cohorts, and performed analysis
on the level and course of FEV1 with additional adjust-
ment for cohort. We studied also two other models (reces-
sive/dominant = mutant/wild type homozygotes
compared to the rest genotypes) which were reported in
case they showed significant effects in the pooled cohort
analysis. Similarly we investigated whether there was a sig-
nificant interaction between KEAP1 and NFE2L2 geno-
types in relation to the level of FEV1, using two-way
combinations of genetic effects with the highest statistical
power i.e. dominant and additive.
Interaction with smoking
Gene by smoking interaction analysis in relation to the
level of FEV1 was performed on the pooled cohorts using
data from single surveys (i.e. second in the Doetinchem
cohort and last in the Vlagtwedde-Vlaardingen cohort) in
order to ensure the highest cumulative exposure to
tobacco smoke and the highest number of subjects ana-
lyzed. The following interaction terms in two following
regression models were analyzed:
1. SNP by ever/never smoking status in the total popula-
tion with adjustment for ever-smoking status and geno-
types and no adjustment for packyears smoked
2. SNP by packyears smoked within ever smokers with
adjustment for packyears smoked and genotypes
P values < 0.05 were considered to be statistically signifi-
cant (tested 2-sided).





Total duration of follow-up (years) 10 25
Number of visits (median) 3 7
The total number of FEV1 measurements across all visits 3,115 8,159
Follow-up time frame, years 1997–2007 1965–1990
Males, n (%) 541 (47.0) 714 (51.4)
FEV1 change in ml/year, mean (SD) -26.2 (33.4) -20.8 (22.9)
Last available:
FEV1 level in liters, mean (SD) 3.31 (0.80) 2.86 (0.77)
Age in years, median (range) 53.7 (32–76) 52.0 (35–79)
Never smokers, n (%) 372 (32.3) 445 (32.0)
Packyears smoked in ever smokers, median (range) 13.2 (0.004–84.0) 18.9 (0.1–262.2)
FEV1 = Forced Expiratory Volume in 1 second
SD = Standard DeviationRespiratory Research 2009, 10:73 http://respiratory-research.com/content/10/1/73
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Software
LME models were run using S-PLUS (version 7.0). Linkage
Disequilibrium (LD) plots and Hardy-Weinberg Equilib-
rium (HWE) tests were performed with Haploview (ver-
sion 4.1) [30]. We identified, with a probability > 95%,
subjects carrying no, one or two copies of a specific haplo-
type, using the *. out_pairs output file from PHASE soft-
ware (version 2.1) [31,32]. We used MIX software
(version 1.7) [33,34] to meta-analyze results from the
Doetinchem, Vlagtwedde-Vlaardingen and British 1958
Birth cohort [35].
Results
Genetic structure of NFE2L2 and KEAP1
There was an excess of KEAP1 rs1048290 SNP heterozy-
gotes in the Vlagtwedde-Vlaardingen cohort, which
caused a significant deviation (p = 0.01) from HWE (table
2). To eliminate potential genotyping errors as underlying
cause of this, we additionally genotyped KEAP1





The total SNP call rate, % 97.5 96.4







MAF HWE p value Heterozygotes Homozygotes 
mutant
MAF HWE p value
NFE2L2 rs6726395 561 (49.6) 256 (22.7) 47.5 0.91 670 (49.6) 277 (20.5) 45.3 0.82
rs4243387 210 (18.8) 10 (0.9) 10.3 0.69 191 (14.1) 14 (1.0) 8.1 0.07
rs1806649 454 (40.5) 72 (6.4) 26.7 0.27 510 (39.1) 83 (6.4) 25.9 0.55
rs13001694 530 (47.3) 178 (15.9) 39.6 0.74 647 (48.1) 223 (16.6) 40.6 0.82
rs2364723 499 (44.6) 105 (9.4) 31.7 0.38 574 (42.8) 156 (11.6) 33.0 0.42
HaplotypeC 326 (30.4) 41 3.8) 18.9 0.72 402 (32.6) 44 (3.6) 19.1 0.42
HaplotypeD 237 (22.1) 13 1.2) 12.4 0.47 283 (22.9) 14 (1.1) 13.0 0.13
KEAP1 rs1048290 507 (45.5) 147 (13.2) 36.0 0.77 671 (50.6) 164 (12.4) 37.6 0.01
rs11085735 117 (10.4) 5 (0.4) 5.6 0.56 129 (9.6) 2 (0.1) 4.9 0.77
rs1048287 203 (18.0) 18 (1.6) 10.6 0.14 248 (18.4) 11 (0.8) 10.0 0.51
HaplotypeA 520 (47.9) 197 (18.1) 57.7 0.64 659 (51.2) 222 (17.3) 57.0 0.13
HaplotypeB 401 (36.9) 80 (7.4) 26.1 0.27 541 (42.1) 88 (6.8) 28.0 0.14
SNP = Single Nucleotide Polymorphism
HWE = Hardy Weinberg Equilibrium
MAF = Minor Allele Frequency
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2
KEAP1 = Kelch-like ECH-associated protein-1Respiratory Research 2009, 10:73 http://respiratory-research.com/content/10/1/73
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rs9676881 SNP, that is in complete LD with rs1048290
(based on HapMap; distance between the two SNPs = 3.7
kb). This SNP also showed a significant deviation from
HWE (p = 0.01; frequency of 50.6% and 12.4% for heter-
ozygotes and homozygote mutants respectively) in the
Vlagtwedde-Vlaardingen cohort.
Five  NFE2L2  TNR alleles, including three alleles not
observed previously [22] i.e. 2, 6 and 7 CCG repeats, were
identified in the Doetinchem cohort. These three novel
alleles occurred with a total cumulative frequency of 0.4%
(see additional file 1 for details).
The NFE2L2 G(-686)A (rs35652124) SNP, CCG TNR and
rs2364723 SNP were in high LD as well as NFE2L2 C(-
650)A (rs6721961) and rs4243387 SNPs (r2 ≥ 0.96, figure
1). We observed 5 prevalent (>5% frequency) haplotypes
in NFE2L2, and 4 prevalent haplotypes in KEAP1 in both
cohorts (table 3). Two haplotypes in NFE2L2 (haplotypes
C and D) were unique, i.e. they were not tagged by a single
allele of any SNP (table 3). Similarly, 2 haplotypes in
KEAP1 (haplotypes A and B) were unique (table 3).
NFE2L2 and KEAP1 variations and level of FEV1
SNP rs2364723 in NFE2L2 was associated (p = 0.06) with
a lower FEV1 level, and SNP rs11085735 in KEAP1 was sig-
nificantly associated with a higher FEV1 level in the Vlagt-
wedde-Vlaardingen cohort (table 4). Similar, but non-
significant trends for an additive effect were observed in
the Doetinchem cohort, resulting in significant effects in
the pooled cohort analysis (table 4).
Heterozygote subjects for rs2364723 SNP had a signifi-
cantly lower FEV1 level as compared to homozygote wild
type subjects (figure 2), while for the rs11085735 SNP all
between-genotypes differences were significant in the
pooled cohort analysis (figure 3).
Haplotype C in NFE2L2 was associated with higher FEV1
levels using an additive model in the pooled cohort anal-
ysis exclusively (table 4). Haplotype A in KEAP1 was asso-
ciated with higher FEV1 level in a recessive model in the
pooled cohort analysis (table 4). No additional consistent
associations were observed for other SNPs or other genetic
models (data not shown).
Table 3: Characteristics of NFE2L2 and KEAP1 haplotypes occurring with >5% frequency in the two cohorts studied
Gene Haplotype SNP* Frequency [%]
rs6726395-rs4243387-rs1806649- rs13001694-rs2364723 Doetinchem cohort Vlagtwedde-Vlaardingen cohort
NFE2L2 A 0-0-0-0-1 31.0 32.5
B 1-0-1-1-0 25.0 24.5
C 0-0-0-0-0 18.9 19.1
D 1-0-0-1-0 12.4 13.0
E 1-1-0-0-0 9.3 7.0
- Rare pooled 3.6 3.9
rs1048290-rs11085735-rs1048287
KEAP1 A 0-0-0 57.7 57.0
B 1-0-0 26.1 28.0
C1 - 0 - 1 9 . 8 9 . 7
D0 - 1 - 0 5 . 5 4 . 9
- Rare pooled 0.9 0.4
*0/1 corresponds to the major/minor allele of SNPs
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2
KEAP1 = Kelch-like ECH-associated protein-1.Respiratory Research 2009, 10:73 http://respiratory-research.com/content/10/1/73
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Interaction between SNPs in NFE2L2 and KEAP1
There was no significant interaction between SNPs in
KEAP1  and  NFE2L2  (using combinations of dominant
and/or additive effects) in relation to the level of FEV1 in
the pooled cohort analysis (data not shown).
Interaction between smoking and NFE2L2 and KEAP1 
variations and level of FEV1
We observed no significant interaction between ever/
never smoking status and variations in NFE2L2 or KEAP1
in relation to the level of FEV1. Yet the effect of
rs11085735 in KEAP1 was significant only in never smok-
ers, while the effect of rs2364723 and haplotype C in
NFE2L2 was significant only in ever smokers (table 5). In
the pooled cohort analysis we observed significant inter-
actions between packyears smoked with two linked varia-
tions in KEAP1  i.e. rs1048290 (BINT  = 1.9 ml/
(packyear*allele number) SEINT = 0.9 p = 0.03) and hap-
lotype B (BINT = 1.9 ml/(packyear*allele number) SEINT =
0.9 p = 0.04). In the single cohort analysis these interac-
tion terms were not significant (p > 0.10 for both
cohorts).
SNPs in NFE2L2 and KEAP1 and course of FEV1
We did not observe any significant effect of SNPs in
NFE2L2 and/or KEAP1 on the course of FEV1 in either of
the cohorts nor in the pooled cohort analysis for any
genetic model tested (see table 6 for additive effects).
Discussion
The current study shows that polymorphisms in antioxi-
dant transcription factor NFE2L2 and its repressor KEAP1
affect the level of FEV1 in the general population.
NFE2L2 is required for the transcription initiation of
many antioxidant-related genes including candidate
genes for lung excess function loss and COPD develop-
ment such as Heme Oxygenase 1 and Glutamate Cysteine
Ligase [11,27,36]. Moreover, murine models have shown
that the Nfe2l2 depletion in vivo results in elastase- [17]
and cigarette smoke-induced [18] emphysema develop-
ment. Thus a functional genetic impairment concerning
NFE2L2 and/or its cytosolic repressor KEAP1 would likely
result in detrimental consequences in vivo.
It has been shown that lung function is genetically deter-
mined [2,3], however so far only low-prevalent polymor-
phisms have been consistently associated with COPD
development across independent studies, i.e. the
Glu342Lys substitution in SERPINA1 (frequency 1%–3%
in Caucasians) that leads to a1-antitrypsin deficiency [6-8]
and the Arg213Gly substitution in Superoxide Dismutase 3
(frequency 1%–2% in Caucasians) [9,10], suggesting that
NFE2L2 and KEAP1 linkage disequilibrium plots (100·r2) in the Doetinchem cohort (n = 1,152) Figure 1
NFE2L2 and KEAP1 linkage disequilibrium plots (100·r2) in the Doetinchem cohort (n = 1,152). *given for the wild 
type (5 CCG repeats) and the mutant (4 CCG repeats) allele NFE2L2 = Nuclear Factor Erythroid 2-Like 2 KEAP1 = Kelch-like ECH-
associated protein-1.Respiratory Research 2009, 10:73 http://respiratory-research.com/content/10/1/73
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low-prevalent SNPs are important contributors to COPD
development. Detection of the effect provided by such
low prevalent SNPs often requires large sample sizes, even
when the effect size is substantial. Similarly, small genetic
effects for highly prevalent variations, such as those geno-
typed in the current study, need to be assessed in large
sample sizes. Therefore, we used all available FEV1 meas-
urements in both cohorts, in order to achieve the highest
possible statistical power. Moreover, we additionally per-
formed analyses on the pooled cohorts including over
2,500 subjects with over 11,000 FEV1 measurements.
In our opinion the most convincing association shown in
the current study was that the rs11085735 SNP in KEAP1
significantly associated with higher FEV1  levels in the
pooled cohort as well as in both cohorts analyzed sepa-
rately, yet using different genetic models. This SNP is
located in the intron 3 of KEAP1, relatively close (73 bp)
to the exon 3 of this gene, and thus it might have func-
tional consequences e.g. via affecting KEAP1 mRNA splic-
ing. Haplotype A in KEAP1 was associated with higher
FEV1 level in the Doetinchem cohort and in the pooled
cohort analysis using a recessive model only. Since this
haplotype does not tag any SNP that was investigated in
the current study, it may be in linkage disequilibrium with
another functional SNP that is either not known yet or is
located outside the region that was selected for tagging.
SNP rs2364723 and haplotype C in NFE2L2 were associ-
ated with the level of FEV1 in the pooled cohort analysis,
as caused by a similar though not significant trends
present in both cohorts. SNP rs2364723 is in almost com-
Table 4: Additive effects of genetic variations in NFE2L2 and KEAP1 on the level of FEV1
Gene Variation Doetinchem cohort Vlagtwedde-Vlaardingen cohort Pooled cohorts
B [ml] 95% CI p B [ml] 95% CI p p
NFE2L2 rs6726395 -13.8 -51.0 – 23.4 0.47 14.1 -17.9 – 46.1 0.39 0.827
rs4243387 0.2 -61.9 – 62.3 0.99 20.6 -36.5 – 77.7 0.48 0.620
rs1806649 -44.5 -87.3 – -1.7 0.04 0.2 -36.7 – 37.1 0.99 0.150
rs13001694 -20.9 -58.7 – 16.9 0.28 13.0 -19.5 – 45.5 0.43 0.948
rs2364723 -22.9 -63.6 – 17.8 0.27 -32.1 -65.4 – 1.2 0.06 0.026
Haplotype C 44.8 -3.4 – 93.0 0.07 24.3 -17.8 – 66.4 0.26 0.040
Haplotype D 47.0 -12.1 – 106.1 0.11 21.2 -29.7 – 72.1 0.41 0.064
KEAP1 rs1048290 12.4 -26.3 – 51.1 0.53 -6.5 -40.8 – 27.8 0.71 0.784
rs11085735 69.9 -9.3 – 149.1 0.08 97.1 22.4 – 171.8 0.01 0.003
rs1048287 -11.9 -70.8 – 47.0 0.69 -33.2 -86.3 – 19.9 0.22 0.287
Haplotype A* 23.9 -13.8 – 61.6 0.21 7.0 -26.5 – 40.5 0.68 0.206
Haplotype B 8.9 -33.2 – 51.0 0.68 4.6 -32.5 – 41.7 0.81 0.601
Significant p values are depicted in bold
* for the recessive effect: B = 76.8 ml (95% CI: 8.0–145.6), p = 0.03 (Doetinchem cohort) and B = 45.1 ml (95% CI: -15.5–105.7) p = 0.14 
(Vlagtwedde-Vlaardingen cohort); p = 0.01 in the pooled cohort analysis
Parameter estimate B (corresponding to the "per-allele" effect on the level of FEV1 in ml), its 95% Confidence Interval and p value are estimated for 
genetic variations in NFE2L2 and KEAP1 using Linear Mixed Effect model analysis on FEV1 level adjusted for genotypes (coded: 0 = homozygotes wild 
type, 1 = heterozygotes, 2 = homozygotes mutant) packyears smoked, sex, age, height and correlation of FEV1 measurements within subjects and 
cohort binary variable for the pooled cohorts analysis.
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2
KEAP1 = Kelch-like ECH-associated protein-1
FEV1 = Forced Expiratory Volume in 1 second
CI = Confidence IntervalRespiratory Research 2009, 10:73 http://respiratory-research.com/content/10/1/73
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Mean adjusted FEV1 level for heterozygote and homozygote mutant genotypes of the NFE2L2 rs2364723 SNP as compared to  wild type Figure 2
Mean adjusted FEV1 level for heterozygote and homozygote mutant genotypes of the NFE2L2 rs2364723 SNP 
as compared to wild type. Mean adjusted effects (squares) and corresponding 95% Confidence Intervals (bars) are pre-
sented. *p < 0.05 as compared to wild type. NFE2L2 = Nuclear Factor Erythroid 2-Like 2. FEV1 = Forced Expiratory Volume in 1 
second.
Mean adjusted FEV1 level for heterozygote and homozygote mutant genotypes of the KEAP1 rs11085735 SNP as compared to  wild type Figure 3
Mean adjusted FEV1 level for heterozygote and homozygote mutant genotypes of the KEAP1 rs11085735 SNP 
as compared to wild type. Mean adjusted effects (squares) and corresponding 95% Confidence Intervals (bars) are pre-
sented. * p < 0.05 for homozygote mutant genotype as compared to wild type or heterozygotes. † p < 0.05 for heterozygote 
genotype as compared to homozygote wild type or homozygote mutant. ‡ p < 0.05 for all between-genotype comparisons. 
KEAP1 = Kelch-like ECH-associated protein-1. FEV1 = Forced Expiratory Volume in 1 secondRespiratory Research 2009, 10:73 http://respiratory-research.com/content/10/1/73
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plete LD with the recently described promoter polymor-
phisms i.e. G(-686)A (rs35652124) and CCG
Trinucleotide repeat (figure 1) [22], implicating a role in
the regulation of NFE2L2 transcription. We found no evi-
dence for an association of another previously identified
functional  NFE2L2  SNP (i.e. C(-650)A (rs6721961)
tagged by us with rs4243387 SNP) [23].
None of the analyzed genetic variations showed a signifi-
cantly different effect on the level of FEV1 between never
and ever smokers, yet the effects provided by NFE2L2
rs2364723 SNP and haplotype C were more prominent in
ever smokers while the effect of KEAP1 rs11085735 SNP
was significant in never smokers exclusively. Interestingly
another variation in KEAP1 (i.e. rs1048290 linked with
haplotype B) showed a protective effect on the level on
FEV1 in interaction with packyears smoked within ever
smokers. The observed association of the level of FEV1 and
the interaction between rs1048290 SNP and smoking can
be somewhat weakened by a deviation from HWE
observed for this SNP in one of the cohorts studied. Since
the common cause of such deviation is a genotyping error,
we have genotyped another, completely correlated,
rs9676881 SNP, which also showed significant deviation
from HWE. This suggests that genotyping error was not a
cause of the observed deviation from HWE. Significant
results obtained in the analysis stratified by smoking sta-
tus (ever and never smokers), or in the gene by packyears
interaction analysis did not reach significance in either of
the cohorts analyzed separately. Since this could be due to
insufficient power provided by single cohorts, subsequent
studies are warranted.
Table 5: Additive effects of NFE2L2 and KEAP1 SNPs on the level of FEV1 in never- and ever-smokers
Doetinchem cohort (n = 1,152)
second survey
Vlagtwedde-Vlaardingen cohort (n = 1,390)
last survey
Gene Variation Never smokers Ever smokers Never smokers Ever smokers
B [ml] SE p B [ml] SE p B [ml] SE p B [ml] SE p
NFE2L2 rs6726395 -33.1 34.1 0.33 -3.4 24.2 0.89 9.7 28.3 0.73 6.4 22.7 0.78
rs4243387 15.5 55.5 0.78 -1.2 41.1 0.98 3.9 56.0 0.94 12.8 38.6 0.74
rs1806649 -97.1 37.7 0.01 -19.0 28.4 0.50 40.6 31.5 0.20 -13.1 26.6 0.62
rs13001694 -54.5 34.7 0.12 -16.0 24.5 0.52 13.5 28.2 0.63 5.6 23.3 0.81
rs2364723 21.5 37.3 0.56 -36.6 26.8 0.17 -3.2 28.4 0.91 -36.2 24.0 0.13
Haplotype C 3.5 44.6 0.94 54.2 31.3 0.08 -22.9 35.2 0.52 47.5 30.5 0.12
Haplotype D 86.7 59.1 0.14 19.5 37.0 0.60 -40.3 42.5 0.34 38.7 37.1 0.30
KEAP1 rs1048290 -0.8 35.3 0.98 17.0 25.5 0.51 -21.8 29.2 0.46 44.6 24.6 0.07
rs11085735 116.2 75.8 0.13 64.6 50.4 0.20 112.2 60.8 0.07 23.5 54.5 0.67
rs1048287 -25.0 53.8 0.64 -10.4 38.7 0.79 -56.8 44.0 0.20 5.1 38.6 0.90
Haplotype A* 25.8 34.0 0.45 22.1 24.9 0.38 4.8 28.8 0.87 36.7 23.8 0.12
Haplotype B 12.3 38.3 0.75 2.3 27.8 0.93 3.6 30.7 0.91 46.3 26.7 0.08
P values depicted in bold indicate associations significant (p < 0.05) in the pooled cohort analysis within never- or ever-smokers.
*p < 0.05 for a positive recessive effect in ever and never smokers in the pooled cohort analysis (p > 0.05 for the analysis concerning separate 
cohorts)
None of the SNP in any model showed significantly different effect between never and ever smokers as tested with the pooled cohort linear 
regression analysis containing interaction term (binary variable reflecting smoking status) adjusted for height, sex, age, cohort and ever/never 
smoking status. Two underlined KEAP1 variations showed a significant interaction with packyears smoked in an additive model within ever-smokers 
in the pooled cohort analysis:
rs1048290: BINT = 1.9 ml/(packyear*number of alleles) SEINT = 0.9 p = 0.03
Haplotype B: BINT = 1.9 ml/(packyear*number of alleles) SEINT = 0.9 p = 0.04Respiratory Research 2009, 10:73 http://respiratory-research.com/content/10/1/73
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Using publicly available data on the British 1958 Birth
cohort [35], we checked whether our results on the signif-
icant association of SNPs with the level of FEV1 could be
replicated in this independent population. The additive
effects provided by. rs11085735 in KEAP1 and rs2364723
in NFE2L2 were not significant, p values being 0.11 and
0.59–0.70 (depending on the genotyping method)
respectively. However, both associations were in the same
direction as found in our two Dutch cohorts, i.e. positive
for rs11085735 in KEAP1 (B = 52.7 ml/allele, 95% Confi-
dence Interval (CI) = -12.6 – 118.0) and negative for
rs2364723 in NFE2L2 (B = -7.3 ml/allele, 95% CI = -44.3
– 29.6, representing higher p value). A subsequent meta-
analysis of the Doetinchem, Vlagtwedde-Vlaardingen and
British 1958 Birth cohorts showed a higher significant
protective effect of the KEAP1 SNP on the level of FEV1 (p
= 0.0008) as compared to the pooled analysis in the two
Dutch cohorts (p = 0.003, table 4). The p value of the
additive and detrimental effect of the rs2364723 SNP was
significant as well (0.036–0.046, depending on the geno-
typing technology in the British 1958 Birth Cohort), yet
higher than the p value provided by the pooled analysis in
the two Dutch cohorts (i.e. p = 0.026, table 4).
Conclusion
Our study performed in two independent Dutch cohorts
shows that genetic variations in KEAP1 and NFE2L2 affect
the level, but not the longitudinal course of FEV1 in the
general population. Therefore, it remains for future con-
siderations whether these SNPs play a role in the develop-
ment or growth of the lung. Given the importance of both
genes in the regulation of oxidative stress in the lung, fur-
ther studies focusing on the NFE2L2-KEAP1 pathway are
warranted.
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Table 6: Additive effects of genetic variations in NFE2L2 and KEAP1 on the longitudinal course of FEV1
Gene Variation Doetinchem cohort Vlagtwedde-Vlaardingen cohort Pooled cohorts
B [ml/yr] 95% CI p B [ml/yr] 95% CI p p
NFE2L2 rs6726395 0.2 -2.5 – 2.9 0.88 0.1 -1.5 – 1.7 0.90 0.873
rs4243387 -1.2 -5.6 – 3.2 0.60 -1.9 -4.8 – 1.1 0.21 0.106
rs1806649 1.5 -1.6 – 4.5 0.35 1.0 -1.0 – 3.0 0.31 0.151
rs13001694 0.0 -2.7 – 2.7 1.00 0.7 -1.0 – 2.4 0.40 0.337
rs2364723 -0.3 -3.2 – 2.6 0.84 -0.6 -2.3 – 1.1 0.50 0.368
Haplotype C -0.3 -3.8 – 3.1 0.85 0.9 -1.3 – 3.1 0.40 0.401
Haplotype D -2.3 -6.6 – 2.0 0.29 0.0 -2.6 – 2.5 0.98 0.627
KEAP1 rs1048290 -2.0 -4.7 – 0.8 0.16 1.0 -0.8 – 2.8 0.28 0.907
rs11085735 3.6 -2.1 – 9.4 0.22 -0.7 -4.7 – 3.3 0.72 0.774
rs1048287 -1.8 -5.9 – 2.4 0.41 -0.4 -3.1 – 2.4 0.80 0.614
Haplotype A -1.3 -4.0 – 1.4 0.35 0.8 -1.0 – 2.5 0.38 0.817
Haplotype B -1.6 -4.6 – 1.4 0.30 1.5 -0.5 – 3.4 0.14 0.573
Parameter estimate B (corresponding to the "per-allele" effect on the change in FEV1 in ml/yr), its 95% Confidence Interval and p value are 
estimated for genetic variations in NFE2L2 and KEAP1 using Linear Mixed Effect model analysis on FEV1 level adjusted for genotypes (coded: 0 = 
homozygotes wild type, 1 = heterozygotes, 2 = homozygotes mutant), age at entry, sex, packyears smoked, FEV1 level at baseline (and their 
interaction with time) and correlation of lung function measurements within subjects (random factor assigned to the intercept and time) and cohort 
binary variable for the pooled cohorts analysis.
NFE2L2 = Nuclear Factor (Erythroid-derived 2)-Like 2 
KEAP1 = Kelch-like ECH-associated protein-1 
FEV1 = Forced Expiratory Volume in 1 second
CI = Confidence IntervalRespiratory Research 2009, 10:73 http://respiratory-research.com/content/10/1/73
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